[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633474":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":42,"collaborators":20,"id":45,"slug":20,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":46,"sex":52,"minAge":53,"maxAge":20,"enrollmentInfo":54,"targetDuration":20,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":67,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Institute for Clinical and Experimental Medicine","OTHER_GOV",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Treated patients","ACTIVE_COMPARATOR","Observational cohort of patients receiving 3-OHB",[13],"Dietary Supplement: Ketone Monoester (KE)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIETARY_SUPPLEMENT","Ketone Monoester (KE)","Continous infusion of a commercially available ketone monoester via nasogastric tube.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Marek Sramko, MD, PhD","CONTACT","+420776246127","marek.sramko@ikem.cz",[28],{"facility":29,"status":30,"city":31,"state":31,"zip":32,"country":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Institute for Clinical and Experimental Medicine (IKEM)","RECRUITING","Prague","14021","Czechia",{"type":35,"coordinates":36},"Point",[37,38],14.42076,50.08804,{"lat":38,"lon":37},[41],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},{"type":43,"investigatorFullName":23,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Head of Department of Acute Cardiology","100633474",false,"NCT07527156","Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure","Feasibility and Safety of Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure","KADHEF-2","Inclusion Criteria:\n\n* LVEF \\\u003C35%\n* Acute heart failure with low cardiac output syndrome or cardiogenic shock\n\nExclusion Criteria:\n\n* Severe liver failure\n* Severe acidosis\n* Inability to insert nasogastric tube\n* Gastric paralysis \u002F ileus\n* Repeated vomiting\n* Severe hypokalemia","ALL","18 Years",{"count":55,"type":56},12,"ESTIMATED","INTERVENTIONAL",[59],"PHASE4","This study will evaluate the feasibility and safety of achieving therapeutic concentrations of beta-hydroxybutyrate using continuous infusion of D-beta-hydroxybutyrate monoester administered via a nasogastric tube in patients with acutely decompensated heart failure with reduced left ventricular ejection fraction.",[62,63,64,65,66],"Acute Heart Failure (AHF)","Cardiogenic Shock","Heart Failure","Ketones","Ketone Body Metabolism",[68,69,70],"acute heart failure","ketones","ketone body","2026-04-07",{"date":73,"type":74},"2026-04-14","ACTUAL",{"date":76,"type":74},"2026-04-04",{"date":78,"type":56},"2027-03-31",{"name":5,"class":6},1]